US 10,376,575 B2
MVA vaccine for delivery of a UL128 complex and preventing CMV infection
Don J. Diamond, Glendora, CA (US); and Felix Wussow, Duarte, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by CITY OF HOPE, Duarte, CA (US)
Filed on Mar. 12, 2018, as Appl. No. 15/919,110.
Application 15/919,110 is a continuation of application No. 14/606,973, filed on Jan. 27, 2015, granted, now 9,931,395.
Application 14/606,973 is a continuation of application No. PCT/US2013/032554, filed on Mar. 15, 2013.
Claims priority of provisional application 61/676,846, filed on Jul. 27, 2012.
Prior Publication US 2018/0303930 A1, Oct. 25, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24143 (2013.01); C12N 2799/023 (2013.01); C12N 2800/204 (2013.01)] 20 Claims
 
1. An expression system comprising a bacterial artificial chromosome (BAC) construct, the BAC construct comprising a viral vector inserted with DNA sequences that encode cytomegalovirus (CMV) proteins or antigenic fragments thereof that form a UL128 complex, wherein the viral vector is derived from a poxvirus.